PhRMA white paper on ADME pharmacogenomics

J Clin Pharmacol. 2008 Jul;48(7):849-89. doi: 10.1177/0091270008319329. Epub 2008 Jun 4.


Pharmacogenomic (PGx) research on the absorption, distribution, metabolism, and excretion (ADME) properties of drugs has begun to have impact for both drug development and utilization. To provide a cross-industry perspective on the utility of ADME PGx, the Pharmaceutical Research and Manufacturers of America (PhRMA) conducted a survey of major pharmaceutical companies on their PGx practices and applications during 2003-2005. This white paper summarizes and interprets the results of the survey, highlights the contributions and applications of PGx by industrial scientists as reflected by original research publications, and discusses changes in drug labels that improve drug utilization by inclusion of PGx information. In addition, the paper includes a brief review on the clinically relevant genetic variants of drug-metabolizing enzymes and transporters most relevant to the pharmaceutical industry.

Publication types

  • Review

MeSH terms

  • Arylsulfotransferase / genetics
  • Catechol O-Methyltransferase / genetics
  • Cytochrome P-450 Enzyme System / genetics
  • Drug Design
  • Drug Industry
  • Drug Interactions
  • Genotype
  • Glucuronosyltransferase / genetics
  • Humans
  • Multidrug Resistance-Associated Protein 2
  • Multidrug Resistance-Associated Proteins / genetics
  • Pharmacogenetics*
  • Pharmacokinetics*
  • Polymorphism, Genetic


  • Multidrug Resistance-Associated Protein 2
  • Multidrug Resistance-Associated Proteins
  • Cytochrome P-450 Enzyme System
  • Catechol O-Methyltransferase
  • UGT1A1 enzyme
  • Glucuronosyltransferase
  • Arylsulfotransferase
  • SULT1A1 protein, human